Phospho-EGFR (Y992) Recombinant Rabbit Monoclonal Antibody - BSA and Azide free [PSH23-63] (HA751904)

UNIPROT #

P00533

PROTEIN NAME

Phospho-EGFR (Y992)

SYNONYMS

Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody;Cell growth inhibiting protein 40 antibody;Cell proliferation inducing protein 61 antibody;EGF R antibody;EGFR antibody;EGFR_HUMAN antibody;Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody;Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian) antibody;Epidermal growth factor receptor antibody;erb-b2 receptor tyrosine kinase 1 antibody;ERBB antibody;ERBB1 antibody;Errp antibody;HER1 antibody;mENA antibody;NISBD2 antibody;Oncogen ERBB antibody;PIG61 antibody;Proto-oncogene c-ErbB-1 antibody;Receptor tyrosine protein kinase ErbB 1 antibody;Receptor tyrosine-protein kinase ErbB-1 antibody;SA7 antibody;Species antigen 7 antibody;Urogastrone antibody;v-erb-b Avian erythroblastic leukemia viral oncogen homolog antibody;wa2 antibody;Wa5 antibody

SUBCELLULAR LOCATION

Cell membrane, Nucleus membrane, Nucleus, Endoplasmic reticulum membrane, Golgi apparatus membrane, Endosome.

FUNCTION

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.